20H·

Novo Nordisk Dip

The Danish pharmaceutical company Novo Nordisk $NOVO B (-0,19 %) has suffered a setback in the development of an Alzheimer's drug. The tested active substance semaglutide, also the basis of the well-known weight loss injection Wegovy, did not achieve its main objective in a decisive phase 3 study with an older, orally administered version: to slow the progression of cognitive decline in Alzheimer's patients, as the company announced on Monday

4 Commentaires

TradingHase@TradingHase

13H

Bullshit! It was not a development towards an Alzheimer's drug, but a study to see whether the drug would also have positive effects in Alzheimer's research.
The drug was not priced into profit expectations.

•

MEMO@MEMO1993

@TradingHase right, well, someone is reading data, but everything that is big is talked to death when it drops. The only thing that bothers me is the debt, the share price would not be where it is today if they had maintained or reduced spending, but then there is no future.

••

A Z.@GreedyA

@MEMO1993 oh facebook was also talked to death, the price has now quintupled. I bought 500 shares and am waiting to make sure I don't miss out on Novo

•

MEMO@MEMO1993

@GreedyA but i also think many people don't understand why they are correcting kruse. I'll be happy to hear what the people at nvidia have to say when there is less demand and the share price has been stagnating for 3 years.

••